Evidence mapPaperPMID 40230204Full record

ReviewDiabetes, obesity & metabolism2025

Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features.

Carmella Evans-Molina, Richard A Oram

Abstract readReview
In one paragraph

Review in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carmella Evans-MolinaDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-7764-8663
Richard A OramClinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.

Funding

PILOT AND FEASIBILITY (P/F) PROGRAMP30DK057521 · MASSACHUSETTS GENERAL HOSPITAL · 2000 to 2005
$8.2M
Interferon Signaling in the T1D Islet MicroenvironmentU01DK127786 · UNIVERSITY OF CHICAGO · 2025 to 2025
$3.5M
Translation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7M
Implications of Changes in Islet Exosomal Cargo in Type 1 DiabetesR01DK133881 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$653k
Indiana University clinical Center for acute pancreatitis and diabetes clinical research networkU01DK127382 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$505k
β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes PathogenesisR01DK127308 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2022 to 2022
$427k
Control of beta cell function and survival by RYR2-mediated calcium signalsR01DK127236 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$420k
BLRD VA I01 BX001733Breakthrough T1DLeona M. and Harry B. Helmsley Charitable TrustNIDDK NIH HHS P30 DK057521NIDDK NIH HHS P30 DK097512NIDDK NIH HHS P30-DK-097512NIDDK NIH HHS R01 DK093954NIDDK NIH HHS R01DK093954NIDDK NIH HHS R01 DK127236NIDDK NIH HHS R01DK127236NIDDK NIH HHS R01 DK127308NIDDK NIH HHS R01DK127308NIDDK NIH HHS R01 DK133881NIDDK NIH HHS R21 DK119800NIDDK NIH HHS U01 DK127382NIDDK NIH HHS U01 DK127786NIDDK NIH HHS U01DK127786NIDDK NIH HHS UC4 DK104166NIDDK NIH HHS UC4DK104166U.S. Department of Veterans Affairs I01BX001733
6 · The paper itself

Abstract

Type 1 diabetes (T1D) has been historically regarded as a childhood-onset disease; however, recent epidemiological data indicate that adult-onset T1D accounts for a substantial proportion of cases worldwide. There is evidence that adult-onset T1D is associated with the classic T1D triad of elevated genetic risk, the presence of islet-specific autoantibodies and progression to severe insulin deficiency. In this article, we review our understanding of the commonalities and differences between childhood and adult-onset T1D, and we highlight significant knowledge gaps in our understanding of the diagnosis, incidence, trajectory and treatment of adult-onset T1D. Compared to children, adults presenting with T1D exhibit differences in genetic risk, immunologic profiles and metabolic outcomes, including differences in the type and number of autoantibodies present, genetic associations and total genetic burden, rates of C-peptide decline, the persistence of C-peptide in long-duration disease and glycaemic control. In addition, obesity and metabolic syndrome are increasingly common in adults, which not only blurs the clinical distinction of adult-onset T1D from type 2 diabetes (T2D) but also likely contributes to differences in metabolic outcomes and rates of progression. Because T2D is so prevalent in the adult population, adult-onset T1D is misclassified as T2D in at least one in three cases, leading to delays in appropriate treatment. Current diagnostic tools, including autoantibody testing and C-peptide measurement, are underutilised or lack specificity in distinguishing adult-onset T1D from atypical T2D. Additionally, the impact of different responses to disease-modifying therapy between adults and children is unclear. Addressing these knowledge gaps requires expanded epidemiological studies, diverse patient registries and refined classification criteria to improve early detection and treatment strategies. A deeper understanding of adult-onset T1D will be critical to reduce the burden of misdiagnosis, lead to earlier diagnosis and treatment and optimise population-based screening approaches in this under-recognised population. PLAIN LANGUAGE SUMMARY: Type 1 diabetes (T1D) is an autoimmune disease that causes metabolic and nutritional complications due to the destruction of insulin-producing pancreatic β cells. T1D was formerly known as "juvenile diabetes" because it was assumed that most cases occurred in childhood; however, recent epidemiological data show that nearly half of all T1D cases are diagnosed in adulthood. Despite the high prevalence of adult-onset T1D, there are challenges with correctly diagnosing T1D in adulthood, and significant knowledge gaps remain regarding the incidence, trajectory, and treatment of adult-onset T1D. In this article, we summarize the current understanding of commonalities and differences between childhood and adult-onset T1D. Particularly, we highlight age-related differences in genetic risk, immunologic profiles, and metabolic outcomes and complications. Finally, we highlight key gaps in our understanding of adult-onset T1D that need to be addressed to reduce the burden of misdiagnosis and allow for better screening and treatment of T1D in adulthood.

Indexed as

Diabetes Mellitus, Type 1AdultAge of OnsetAutoantibodiesChildDiabetes Mellitus, Type 2Diagnosis, DifferentialDisease ProgressionGenetic Predisposition to DiseaseHumansIncidenceAutoantibodiesbasal insulinbeta cell functiondiabetes complicationstype 1 diabetes

Identifiers

PMID40230204
PMCPMC12312822

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.